Hester van Diepen's guest appearances

Hester van Diepen

USH Talks

Jacque Duncan

Moa Wahlqvist

Kumar Alagramam

Shannon Boye

Megan Cote

Hannie Kremer

Margaret Kenna

Karmen Trzupek

Marcia Brooks

Hans Jørgen Wiberg

Gema García-García

Monte Westerfield

OwlTail

In this USH talk, Hester van Diepen provides an overview of the Usher development program at ProQR Therapeutics as an approach for possible future treatment of USH2A-associated retinitis pigmentosa.Speaker Bio: Dr. Hester van Diepen currently leads the Usher syndrome development program at ProQR Therapeutics. ProQR Therapeutics is a young biotech company based in Leiden in the Netherlands focusing on the development of RNA therapies for rare genetic diseases. Hester joined ProQR in 2015 after obtaining her PhD in Ophthalmology and Neurophysiology at the Leiden University Medical Center. Since joining ProQR she entirely focuses on the Usher development programs to develop an RNA therapy as a treatment for retinitis pigmentosa caused by mutations in the USH2A gene.

In this USH talk, Hester van Diepen provides an overview of the Usher development program at ProQR Therapeutics as an approach for possible future treatment of USH2A-associated retinitis pigmentosa.<br><br>Speaker Bio: Dr. Hester van Diepen currently leads the Usher syndrome development program at ProQR Therapeutics. ProQR Therapeutics is a young biotech company based in Leiden in the Netherlands focusing on the development of RNA therapies for rare genetic diseases. Hester joined ProQR in 2015 after obtaining her PhD in Ophthalmology and Neurophysiology at the Leiden University Medical Center. Since joining ProQR she entirely focuses on the Usher development programs to develop an RNA therapy as a treatment for retinitis pigmentosa caused by mutations in the USH2A gene.

ProQR Usher Syndrome Type 2 Development Program, Hester van Diepen, PhD